• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病患者艰难梭菌感染的分子分型及临床特征:一项回顾性研究

Molecular typing and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease: A retrospective study.

作者信息

Li Jiayiren, Yang Jing, Ouyang Zirou, Ren Minghui, Zhao Jianhong

机构信息

Hebei Provincial Center for Clinical Laboratories, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

出版信息

J Glob Antimicrob Resist. 2025 Jun;43:188-197. doi: 10.1016/j.jgar.2025.04.011. Epub 2025 Apr 24.

DOI:10.1016/j.jgar.2025.04.011
PMID:40287014
Abstract

OBJECTIVES

The increasing incidence of Clostridioides difficile infection (CDI) has been associated with poorer prognosis of patients with inflammatory bowel disease (IBD). However, relevant data are limited in China. The aim of this study was to clarify the molecular types and clinical characteristics of C. difficile in IBD patients in China.

METHODS

Stool samples were collected, cultured anaerobically, and tested for glutamate dehydrogenase and C. difficile toxins A and B. Toxigenic C. difficile isolates were subjected to multi-locus sequence typing and antimicrobial susceptibility testing. Clinical data were collected to compare IBD and non-IBD patients with CDI, and to determine the risk factors associated with CDI in IBD patients.

RESULTS

The incidence of CDI was significantly higher in IBD patients than non-IBD patients (27.2% vs. 9.0%, respectively). Among IBD patients, the dominant sequence types (STs) were ST54 (20.2%), ST2 (14.9%), ST3 (14.9%), and ST42 (13.2%). The STs with the highest multidrug resistance rates were ST37 (100%), ST35 (100%), and ST42 (73.3%). In IBD patients, hospitalization within 6 months and use of 5-aminosalicylic acid were independent risk factors for CDI. Other risk factors included the use of proton pump inhibitors, immunosuppressants, and corticosteroids.

CONCLUSION

The incidence of CDI was significantly higher in IBD patients than non-IBD patients. Surveillance of CDI in hospitalized patients should be strengthened to reduce the incidence of CDI in IBD patients.

摘要

目的

艰难梭菌感染(CDI)发病率的上升与炎症性肠病(IBD)患者的预后较差有关。然而,中国的相关数据有限。本研究的目的是阐明中国IBD患者中艰难梭菌的分子类型和临床特征。

方法

收集粪便样本,进行厌氧培养,并检测谷氨酸脱氢酶以及艰难梭菌毒素A和B。对产毒素的艰难梭菌分离株进行多位点序列分型和抗菌药物敏感性测试。收集临床数据以比较IBD和非IBD的CDI患者,并确定IBD患者中与CDI相关的危险因素。

结果

IBD患者中CDI的发病率显著高于非IBD患者(分别为27.2%和9.0%)。在IBD患者中,主要的序列类型(STs)为ST54(20.2%)、ST2(14.9%)、ST3(14.9%)和ST42(13.2%)。多重耐药率最高的STs为ST37(100%)、ST35(100%)和ST42(73.3%)。在IBD患者中,6个月内住院和使用5-氨基水杨酸是CDI的独立危险因素。其他危险因素包括使用质子泵抑制剂、免疫抑制剂和皮质类固醇。

结论

IBD患者中CDI的发病率显著高于非IBD患者。应加强对住院患者CDI的监测,以降低IBD患者中CDI的发病率。

相似文献

1
Molecular typing and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease: A retrospective study.炎症性肠病患者艰难梭菌感染的分子分型及临床特征:一项回顾性研究
J Glob Antimicrob Resist. 2025 Jun;43:188-197. doi: 10.1016/j.jgar.2025.04.011. Epub 2025 Apr 24.
2
Molecular epidemiology and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease from a teaching hospital.教学医院炎症性肠病患者艰难梭菌感染的分子流行病学和临床特征。
J Clin Lab Anal. 2022 Dec;36(12):e24773. doi: 10.1002/jcla.24773. Epub 2022 Nov 17.
3
Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis.儿童和青少年炎症性肠病患者艰难梭菌感染的危险因素:系统评价和荟萃分析。
World J Pediatr. 2022 Jan;18(1):27-36. doi: 10.1007/s12519-021-00486-1. Epub 2021 Nov 20.
4
Clinical characteristics of community-onset Clostridioides difficile infections at a tertiary hospital in mainland China: A fourteen-year (2010-2023) retrospective study.中国大陆一家三级医院社区获得性艰难梭菌感染的临床特征:一项十四年(2010-2023)回顾性研究。
Int J Med Microbiol. 2024 Sep;316:151631. doi: 10.1016/j.ijmm.2024.151631. Epub 2024 Jul 14.
5
Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short- and long-term risks of colectomy in inflammatory bowel disease.系统评价与荟萃分析:艰难梭菌感染对炎症性肠病患者结肠切除短期和长期风险的影响
Aliment Pharmacol Ther. 2017 Apr;45(8):1011-1020. doi: 10.1111/apt.13972. Epub 2017 Feb 16.
6
Systematic review: Clostridium difficile and inflammatory bowel disease.系统评价:艰难梭菌与炎症性肠病。
Aliment Pharmacol Ther. 2011 Feb;33(4):428-41. doi: 10.1111/j.1365-2036.2010.04548.x. Epub 2010 Dec 30.
7
The incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis.中国大陆艰难梭菌感染的发病率和耐药性:系统评价和荟萃分析。
Sci Rep. 2016 Nov 29;6:37865. doi: 10.1038/srep37865.
8
Antimicrobial Combinations as Novel Indicators for Clostridioides difficile infection development: Population-Based, Nested Case-Controlled Study in Japan-The Shizuoka Kokuho Database Study.抗菌药物联合使用作为艰难梭菌感染发生的新指标:基于人群的日本巢式病例对照研究——静冈国保数据库研究
J Infect Chemother. 2025 Feb;31(2):102552. doi: 10.1016/j.jiac.2024.11.002. Epub 2024 Nov 6.
9
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.用于预防成人和儿童艰难梭菌相关性腹泻的益生菌
Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4.
10
Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.成人艰难梭菌相关性腹泻的抗生素治疗
Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD004610. doi: 10.1002/14651858.CD004610.pub5.